UPDATED Apr 16, 2024
Potentially undervalued companies with a strong past performance and robust balance sheet.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
VRTX | US$394.17 | -2.5% | 21.2% | US$102.7b | US$461.45 | PE28.1x | E11.4% | n/a | ||
BMRN | US$90.87 | 2.1% | -7.7% | US$17.4b | US$110.03 | PE102.9x | E30.8% | n/a | ||
INCY | US$53.22 | -3.8% | -27.9% | US$12.0b | US$76.06 | PE20x | E20.1% | n/a | ||
CORT | US$23.39 | -8.1% | 5.6% | US$2.4b | US$42.80 | PE23x | E25.9% | n/a | ||
HRMY | US$29.52 | 0.5% | -10.5% | US$1.7b | US$41.63 | PE13x | E25.8% | n/a | ||
ANIP | US$66.30 | -1.0% | 68.9% | US$1.4b | US$79.80 | PE89.9x | E37.4% | n/a | ||
PNT | US$12.50 | 0.2% | 75.1% | US$1.3b | US$12.50 | PE13.8x | E9.2% | n/a | ||
PCRX | US$26.87 | -5.8% | -38.2% | US$1.2b | US$45.73 | PE29.8x | E29.3% | n/a | ||
MDXG | US$6.23 | -11.3% | 85.4% | US$933.2m | US$12.44 | PE16.4x | E15.0% | n/a | ||
PLX | US$1.14 | -13.6% | -53.3% | US$83.3m | US$13.00 | PE10x | E96.5% | n/a |